Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
79 results about "Dextran sodium sulfate" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Dextran sodium sulfate (DSS) is commonly used in mouse studies to induce a very reproducible colitis that effectively mimics the clinical and histological features of human inflammatory bowel disease (IBD) patients, especially ulcerative colitis.
Excellent lactobacillus reuteri for preventing ulcerative colitis
InactiveCN110591945APrevent effectPromote infiltrationBacteriaDigestive systemUlcerative colitisDisease activity
The present invention provides lactobacillus reuteri for preventing ulcerative colitis. The strain is named as lactobacillus reuteri RAM0101 and deposited on May 27, 2019 at China General Microbiological Culture Collection Center and has a preservation number of CGMCC NO.17853. C57BL / 6N mice are used as test objects, dextran sodium sulfate (DSS) is used to induce the mice to form an ulcerative colitis model and the model is also used to investigate effectiveness of the strain in preventing the ulcerative colitis. The lactobacillus reuteri can relieve weight loss, diarrhea, hematochezia and disease activity index (DAI) score of the ulcerative colitis mice induced by the DSS, protects pathological damages of colon tissues of the mice induced by the DSS, can enhance colon tissue epithelial barrier completeness and is also free of toxin and harms.
Owner:JILIN UNIV
Model for protecting mouse ulcerative colitis by antibacterial peptide C-BF
InactiveCN104031883AReduce enzyme activityIncrease secretionTumor/cancer cellsVeterinary instrumentsUlcerative colitisBowels diseases
The invention discloses a model for protecting mouse ulcerative colitis by antibacterial peptide C-BF. Cathelicin-BF has broad-spectrum antibacterial activity, especially for Gram negative bacteria. Inflammatory bowel diseases (IBDs) comprise ulcerative colitis (UC) and Crohn disease (CD), and pathomechanisms of the diseases are not clear yet. A model for inducing the mouse ulcerative colitis by 3% dextran sulphate sodium (DSS) is built; a PBS solution of the C-BF is subjected to rectal injection once per day, the dose of the C-BF is 5mg / kg, the continuous injection time is one week, a mouse is weighed and the body weight data of the mouse is recorded each day during experimental period, and the rectal bleeding and dung forming situations of the mouse are observed. The model is used for making a research on a protection effect on the mouse UC caused by the C-BF.
Owner:ZHEJIANG UNIV
Method for preparing protamine and dextran sulfate sodium microcapsule
InactiveCN101530767AGood size controlBiocompatibleMicroballoon preparationMicrocapsule preparationMultilayer membraneMicrosphere
The invention relates to a method for preparing the protamine and dextran sulfate sodium microcapsule, comprising the following steps: reacting calcium chloride, sodium carbonate, sodium polystyrene sulfonate or polyallylamine hydrochloride, cetyl trimethyl ammonium bromide, PEO20-PPO70-PEO20 triblock copolymer, polydiallyldimethylamine chloride solution with stirring at the temperature of 10 to 80 DEG C to obtain the calcium carbonate microsphere; fully mixing the obtained calcium carbonate microsphere with the protamine water solution, adsorbing the protamine, removing the protamine not to be adsorbed, fully mixing the calcium carbonate microsphere with the protamine withdextran sulfate sodium containing inorganic salt to adsorb dextran sulfate sodium, removing the dextran sulfate sodium not to be adsorbed; alternately adsorbing to obtain the microcapsule with the protamine and dextran sulfate sodium multilayer membrane core-shell structure; dissolving calcium carbonate in ethylenediaminetetraacetic acid sodiumsalt to obtain the protamine and dextran sulfate sodium microcapsule.
Owner:NINGBO UNIVERSITY OF TECHNOLOGY
Application of codonopsis pilosula polysaccharide as medicine for regulating intestinal flora of human body
InactiveCN109745336AImprove macroscopic pathologySimple structureOrganic active ingredientsDigestive systemDiseaseBacteroides
The invention provides an application of codonopsis pilosula polysaccharide as medicine for regulating intestinal flora of human body, namely the application of codonopsis pilosula polysaccharide as medicine, food or health products for preventing colitis. An acute colitis mouse model is established by using fructo-oligosaccharide, codonopsis pilosula polysaccharide and codonopsis pilosula saponinto be respectively prevented in a healthy mouse model for 21 days and adopting 3% dextran sodium sulfate to be induced for 7 days. The remission of three drugs to macroscopical pathological symptomsof colitis is compared by evaluating changes of body weight, colon length, pathological index of disease, histological section and myeloperoxidase activity of experimental mice and the like. The regulation of drug on intestinal flora of colitis mice is investigated by using the Illumina MiSeq 250 sequencing platform based on the variable region of 16S V3-V4, and dominant bacteria in each drug intervention group are identified, which shows the absorption of the highest exposure amount of monomer saponin in codonopsis pilosula saponin in serum and the cecum, clarifies the mechanism that codonopsis pilosula polysaccharide plays a role in the treatment of diseases by changing the action of intestinal flora on saponin metabolism.
Owner:LANZHOU UNIVERSITY
Method for building dextran sodium sulphate (DSS) induced enteritis mouse model
ActiveCN102813671AReduce mortalityRepeatableOrganic active ingredientsIn-vivo testing preparationsMortality rateDextran
The invention provides a method for building a dextran sodium sulphate induced enteritis mouse model. The method includes the following steps: A, choosing female C57BL / 6 mice with the weight of 19-21g as the objects to build the mouse model; B, dissolving dextran sulphate sodium salt solution in disinfected drinking water to prepare dextran sulphate sodium salt solution with the weight percentage concentration of 2%, and placing the solution in a water bottle for protecting away from the sun, wherein the solution is prepared when required; C, feeding the chosen C57BL / 6 mice in a storageprotect feature (SPF) level animal house, enabling the mice to drink the dextran sulphate sodium salt solution prepared in the step B for six days and then drink the normal drinking water for four days. Accordingly, the chosen C57BL / 6 mice are dextran sodium sulphate induced enteritis mouse models. By means of the method for building the dextran sodium sulphate induced enteritis mouse model, death rate of animals is reduced to be zero, and pathology expressions are the same, so that the model is stable, reliable and repeatable.
Owner:辉源生物科技(上海)有限公司
Application of p-hydroxybenzoic acid in preparing drug for treating inflammatory bowel disease
The invention discloses application of p-hydroxybenzoic acid in preparing a drug for treating an inflammatory bowel disease. At a dose significantly lower than mesalazine, the p-hydroxybenzoic acid can significantly inhibit the increase in disease activity index scores of enteritis model mice induced by dextran sodium sulfate, improve colon length shortening of the colitis model mice, reduce the colonic MPO activity of the mice, and reduce the inflammatory cell infiltration of colon tissues in the colitis model mice. According to the application, the p-hydroxybenzoic acid can alleviate the inflammatory reaction of the DSS-induced inflammatory bowel disease model mice and improve the severity of the inflammatory bowel disease, and can be used for preparing the drug or a health care productfor treating the inflammatory bowel disease.
Owner:GUILIN MEDICAL UNIVERSITY +1
Recombinant bacillus subtilis expressing C30 carotenoid
ActiveCN105838731ARelieves Colitis SymptomsBacteriaMicrobiological testing/measurementDendritic cellGenetic engineering
The invention relates to recombinant bacillus subtilis capable of synthesizing carotenoid 4,4'-diaponeurosporene with 30 carbon atoms (C30), and belongs to the biotechnology genetic engineering field. A bacillus subtilis expression plasmid pMK3-crtmn (which is capable of expressing C30 carotenoid synthases Crtm and Crtn in bacillus subtilis) containing C30 carotenoid synthase genes crtm and crtn is successfully constructed, and is successfully electro-transformed into bacillus subtilis WB800. The WB800 strain after transformation turns from the original color of white to yellow. A pigment component extracted from the recombinant WB800 is identified as 4,4'-diaponeurosporene by high performance liquid chromatography (HPLC). 4,4'-diaponeurosporene can stimulate maturation of dendritic cells, and generated cytokines (IL-6, IL-10, IL-12p70 and TNF[alpha]) have the amount increased, and moreover and have stronger ability to stimulate proliferation of T lymphocytes. With oral administration of the bacillus subtilis capable of synthesizing 4,4'-diaponeurosporene, the dextran sulphate sodium (DSS)-induced mice colitis symptoms can be significantly reduced. The bacillus subtilis capable of producing 4,4'-diaponeurosporene is expected to be developed as probiotics for prevention of colitis.
Owner:NANJING AGRICULTURAL UNIVERSITY
Recombinant human lactoferrin (rhLF) silkworm chrysalis powder as well as preparation method and application thereof
InactiveCN104561098AImprove biological activitySuitable for mass productionPeptide/protein ingredientsMicroencapsulation basedFreeze-dryingUlcerative colitis
The invention relates to recombinant human lactoferrin (rhLF) silkworm chrysalis powder as well as a preparation method and application thereof and belongs to the technical field of biological medicines. A recombinant virus is constructed mainly by adopting a silkworm chrysalis baculovirus expression system, the rhLF is expressed with a silkworm chrysalis serving as a bioreactor, the silkworm chrysalis diseased after being inoculated with the recombinant virus is prepared into freeze-dried powder, the activity of the freeze-dried powder is detected by performing antibacterial experiments in vitro, and the freeze-dried powder is poured into the stomach of a mouse to treat the dextran sulphate sodium (DSS) induced ulcerative colitis of the mouse. The analysis on the disease activity index (DAI) of the mouse and the detection on the content of myeloperoxidase (MPO) in the colonic tissue of the mouse show that the rhLF with antibacterial activity is expressed successfully in the silkworm chrysalis, and the rhLF silkworm chrysalis powder has a certain effect of treating the DSS induced ulcerative colitis of the mouse. The preparation method provided by the invention is simple, is low in cost and is used for preparing a novel oral protein medicine.
Owner:TIANJIN YAOYU BIOLOGICAL TECH
Composition containing resveratrol and used for treating ulcerative colitis
InactiveCN107927775ATo achieve the purpose of treating ulcerative colitisRegulating cytokines in the bodyHydroxy compound active ingredientsDigestive systemAlcoholAdhesive
The invention provides a composition containing resveratrol and used for treating ulcerative colitis. The composition consists of the following components in parts by weight: 1-10 parts of resveratrol, 5-20 parts of a grape seed extract, 10-50 parts of prebiotics and an adhesive which is 2-5% of the total weight of other components, and the binder namely the adhesive is water or an alcohol solution of 80-95%. The components of the composition cooperate for common use, so that the in vivo cell factors can be regulated, and the inflammation can be restrained; and after experiment mice induced with dextran sulfate sodium are intervened with the composition, the symptom of acute colitis is relieved, the weight reduction is restrained, and the colon shrinking degree is obviously improved. The composition preparation is harmonious in color after being brewed and is moderate in mouth feel.
Owner:天津药食同源健康产业有限公司
Application of wedelolactone in preparing drug for resisting ulcerative colitis
InactiveCN105030763AImprove colitis symptomsGood treatment effectDigestive systemHeterocyclic compound active ingredientsInflammatory factorsWedelolactone
The invention relates to an application of Chinese traditional herb monomer wedelolactone as a drug for treating ulcerative colitis. According to the application, wedelolactone is obtained from Chinese traditional herb material eclipta, and the structure of wedelolactone is determined according to spectrum data. Through intragastric administration of wedelolactone, the body weight change of a model mouse is obviously changed, the length of the colon is increased, the inflammation level of the colon is obviously hanged, the NO content reflecting the inflammation degree of the colon is reduced, the activity of myeloperoxidase (MPO) in the colon tissue is reduced, release of inflammatory factors IL-8 of Caco-2 cells excited byIL-1beta is inhibited in vitro. The results of in-vivo and in-vitro experiments show that wedelolactone under certain dosage can obviously inhibit release of the inflammatory factors of the colon tissue, so that the acute ulcerative colitis of the mouse caused by dextran sulphate sodium salt (DSS) can be obviously improved, and therefore, wedelolactone has a novel application as a drug for treating or improving ulcerative colitis.
Owner:CHINA PHARM UNIV
Application of dark plum fruit and extract of dark plum fruit in preparation of drug or health care product for controlling CRC (colorectal cancer)
ActiveCN104800321AImprove weight lossReduce tumor incidenceAntineoplastic agentsFood preparationBowels diseasesLoose Stool
The invention discloses an application of dark plum fruit and an extract of dark plum fruit in control of the CRC (colorectal cancer). On the basis of the conventional efficacy of dark plum fruit, a large quantity of experiments is adopted for intensive study, an AOM-DSS (azoxymethane / dextran sodium sulfate) induced mouse model suffering from bowel disease carcinogenesis is adopted, and study results show that the dark plum fruit and the extract of the dark plum fruit can substantially improve the condition of weight loss of the model mouse in a bowel disease carcinogenesis process, can substantially improve the continuously serious symptoms such as body mass loss, loose stools, hematochezia and the like of the mouse suffering from bowel disease carcinogenesis, can substantially reduce the colonic neoplasm incidence of the mouse suffering from bowel disease carcinogenesis and has very good CRC preventing and controlling efficacy.
Owner:JIANGSU PROVINCIAL HOSPITAL OF TCM
Application of extract of root of Hainan devilpepper in treating of ulcerative colitis in mice
The invention relates to the field of biomedicines, and in particular relates to an effect and a mechanism of extract of root of Hainan devilpepper on dextran sulfate sodium colitis in mice, and the extract can interfere with signaling pathways of NF-kB and MAPKs. The extract is obtained by drying the root of Hainan devilpepper at 40 DEG C, filtering with a 0.7% ammonium oxalate solution for extraction, centrifuging residue, adjusting pH to 4.40 with HCL, again centrifuging, precipitating the residue with ethanol, and drying after centrifugation.
Owner:海南省人民医院
Preparation method and application of 'baicalin-berberine' compound
InactiveCN106963777ASuppress bitternessExcellent in vitro releaseOrganic active ingredientsAntipyreticBerberineAcute ulcerative colitis
The invention relates to a preparation method and application of a 'baicalin-berberine' compound. First, baicalin and berberine are prepared into a yellow floccule through a heating method, and the 'baicalin-berberine' compound is obtained through centrifugation and drying. The compound is uniform in color and luster and lower in toxicity. Compared with a crude drug (berberine) and a physical blend, the compound can remarkably mask the bitter taste of the berberine. The better anti-inflammatory activity better than that of the crude drug can be shown in an acute ulcerative colitis (UC) model mouse induced by 4% dextran sodium sulfate (DSS).
Owner:NINGXIA MEDICAL UNIV
Dextran sulfate sodium-induced chicken enteritis model and building method thereof
InactiveCN106389460AImprove integrityPromote absorptionCompounds screening/testingOrganic active ingredientsBiologyInflammation
The invention discloses a building method for a chicken enteritis model. The method comprises the following steps of (1) dissolving dextran sulfate sodium with a molecular weight of 36-50kDa in chicken drinking water to prepare 0.75-2.5% by weight of a dextran sulfate sodium solution, wherein the dextran sulfate sodium solution is used immediately after being prepared; (2) selecting a 14-18-day-age healthy quick-growth chicken as an object for building the chicken enteritis model; and (3) feeding the selected quick-growth chicken in a chicken house, and enabling the chicken to freely drink the dextran sulfate sodium solution prepared in the step (1) for more than 10 days. The building method for the chicken enteritis model is simple and convenient in operation; the effective dose range of the dextran sulfate sodium solution is wide, so that enteritis models of different pathological degrees can be built; and the method can be suitable for large-scale popularization and application in experiments.
Owner:ANIMAL SCI RES INST GUANGDONG ACADEMY OF AGRI SCI
Hibiscus sabdariffa anthocyanin extract as well as preparation method and application thereof
PendingCN113876821AWide range of usesSimple extraction processAntipyreticAnalgesicsGut floraFatty acid
The invention provides a preparation method of a hibiscus sabdariffa anthocyanin extract. The extraction process is simple, no pollution is caused, and the anthocyanin content is high. The hibiscus sabdariffa anthocyanin extract prepared by the preparation method disclosed by the invention is wide in application, and can be applied to multiple fields of foods, preparation of health-care products and / or medicines. The invention further provides an application of the hibiscus sabdariffa anthocyanin extract to preparation of a medicine for preventing or relieving colitis. The hibiscus sabdariffa anthocyanin extract has the specific effects on preventing or relieving colitis as follows: the hibiscus sabdariffa anthocyanin extract can relieve weight loss of dextran sodium sulfate induced colitis mice, reduce the inflammation level in serum and tissues, relieve shortening and edema of colon, protect intestinal mucosa barriers, increase the total content of short-chain fatty acids in the intestinal tract, maintain the stable state of intestinal flora, and reduce the abundance of harmful bacteria in the intestinal tract.
Owner:JINAN UNIVERSITY
Starch-based capsule coat as well as preparation method and application thereof
ActiveCN113842372AImprove mechanical propertiesStrong electrostatic interactionCosmetic preparationsToilet preparationsCellulosePolymer science
The invention provides a starch-based capsule coat, which is prepared from the following raw materials in percentage by mass: 40-70wt% of anionic / cationic starch, 20-50wt% of a natural product, less than or equal to 10wt% of a plasticizer and the balance of water; the charge of the natural product is opposite to that of the anionic / cationic starch; the natural product comprises at least one of chitosan, carboxymethyl cellulose, sodium alginate, polylysine, dextran, dextran sodium sulfate and sulfonated cellulose. According to the invention, the anionic / cationic starch with charges and the natural product with opposite charges are compounded, the polyelectrolyte material can be formed under the electrostatic interaction, the acting force of the electrostatic interaction of the polyelectrolyte material is far stronger than that of hydrogen bonds and intermolecular interaction, and the polyelectrolyte material has an aggregation effect, so that the starch-based capsule coat has excellent mechanical properties.
Owner:NANJING UNIV OF FINANCE & ECONOMICS
Application of caffeic acid 3,4-dyhydroxy phenethyl ester to preparing medicine for preventing colorectal cancer
InactiveCN108992434APrevent intrusionPrevent infiltrationOrganic active ingredientsAntineoplastic agentsDimethylhydrazineCyclin D1
The invention provides application of caffeic acid 3,4-dyhydroxy phenethyl ester (CADPE) to preparing a medicine for preventing colorectal cancer. The medicine is prepared from CADPE as an active component and a pharmaceutically acceptable carrier. The CAPDE is capable of effectively preventing early-stage occurrence of ICR (Institute for Cancer Research) mouse colorectal cancer induced by 1,2-dimethylhydrazine (DMH) and dextran sulphate sodium salt, has no conspicuous toxicity, and has the function mechanisms of inhibiting inflammatory cell invasion and infiltration and inhibiting NF-KappaB expression in monocyte, inhibiting expression of beta-catenin in aberrant crypt, reducing expression of cell proliferin PCNA and Cyclin D1, an anti-apoptoasis protein surviving and a cancer gene c-Myc,and inhibiting tumor vessel proliferation. Novel treatment means are provided for clinical prevention and treatment on colorectal cancer.
Owner:ZHEJIANG UNIV
Application of modified nano iron oxide in preparation of medicine for preventing and/or treating inflammatory bowel disease
ActiveCN114028423AGood for weight lossImprove colonic bleedingHeavy metal active ingredientsDigestive systemIntestinal tract diseasesBowels diseases
The invention provides an application of modified nano iron oxide in preparation of a medicine for preventing and / or treating inflammatory bowel diseases. The modified nano iron oxide is gamma-Fe2O3 nano particles, positive electricity modified gamma-Fe2O3 nano particles, negative electricity modified gamma-Fe2O3 nano particles or polymer modified gamma-Fe2O3 nano particles. Different modifications are carried out on the nano iron oxide, so that the surfaces of the iron oxide nanoparticles have different charges and potential differences, the purpose of adsorbing different inflammatory proteins in intestinal tracts is achieved, the nano iron oxide adsorbing the inflammatory proteins is discharged out of a body, and the purpose of improving or relieving intestinal diseases is achieved. Experimental results show that the nano iron oxide with different modifications can significantly improve weight loss, disease index increase, colon bleeding, colon shortening, colonic mucosa hyperplasia and colitis response in a dextran sodium sulfate induced inflammatory bowel disease mouse model, so that the inflammatory bowel disease is treated.
Owner:THE GBA NAT INST FOR NANOTECHNOLOGY INNOVATION
Application of dehydrolovastatin to preparation of anti-inflammatory bowel disease medicament
InactiveCN106074500AGood inhibitory effectImprove the level ofOrganic active ingredientsDigestive systemTreatment effectInflammatory Bowel Diseases
The invention discloses an application of dehydrolovastatin to preparation of an anti-inflammatory bowel disease medicament. The prevention and control actions and the action mechanism of the dehydrolovastatin on a mouse inflammatory bowel disease induced by dextran sulfate sodium are disclosed for the first time through tests of building a mouse acute inflammatory bowel disease model, observing the treatment effect of the dehydrolovastatin on the inflammatory bowel disease, and the like. The dehydrolovastatin significantly inhibits the levels of proinflammatory factors TNF-alpha, IL-6 and IL-17 by inhibiting an NF-kappa B signal path, raises the level of an anti-inflammatory factor IL-10, and plays a role in preventing the mouse inflammatory bowel disease induced by 4-percent DSS (Dextran Sulfate Sodium Salt).
Owner:CHONGQING MEDICAL & PHARMA COLLEGE
Application of total saponins of panax japonicus in preparation of ulcerative colitis resisting medicines
InactiveCN105963333AOrganic active ingredientsDigestive systemManagement of ulcerative colitisAcute toxicity testing
The invention discloses an application of total saponins of panax japonicus in preparation of ulcerative colitis resisting medicines. According to the application, the prevention and treatment action and action mechanism of the total saponins of panax japonicus to dextran sulfate sodium induced mouse ulcerative colitis are researched through a series of tests, i.e., extracting the total saponins of panax japonicus, carrying out an acute toxicity test on the total saponins of panax japonicus, modeling a mouse acute ulcerative colitis model and observing the therapeutic action of the total saponins of panax japonicus on ulcerative colitis, and the influence on NF-[kappa]B and PPAR-gamma signal channels caused by the total saponins of panax japonicus is disclosed for the first time. The total saponins of panax japonicus have the effects of treating both symptoms and root causes and being safe and effective during the treatment of the ulcerative colitis.
Owner:CHONGQING MEDICAL & PHARMA COLLEGE
Application of MG53/MG53 mutant-containing composition in preparation of inflammatory bowel disease drug
PendingCN108478800ASignificantly effective in treating ulcerative colitisQuick resultsOrganic active ingredientsPeptide/protein ingredientsMutantDisease activity
The invention provides application of an MG53 / MG53 mutant-containing composition in preparation of a drug for preventing and treating the inflammatory bowel disease. The mutant is non-polar amino acidalanine mutated from a serine site in the Coiled-coil structural domain of MG53. A mouse ulcerative colitis model is built through induction of dextran sulfate sodium (DSS); 5-aminosalicylic acid (5-ASA) is used as a positive drug for contrast; evaluation of a disease activity index (DAI), the length of a colon, a weight change and pathological changes of a colon tissue verifies that the composition has an obvious inhibition effect on the DSS-induced colitis.
Owner:MUDANJIANG YOUBO PHARMA CO LTD
Extraction method and application of morchella extract
ActiveCN113332317ADefinite curative effectRelieve liver damageDigestive systemPlant ingredientsSodium bicarbonateGastric digestion
The invention discloses an extraction method of a morchella extract. The extraction method specifically comprises the following steps of 1, preparing morchella powder; 2, uniformly mixing a product obtained in the step 1 with normal saline to prepare a morchella mixture; 3, adding an acid solution into the morchella mixture obtained in the step 2, and then adding a pepsase solution into the solution to obtain a morchella in-vitro simulated stomach digest; 4, adding a sodium bicarbonate solution into the morchella in-vitro simulated stomach digest obtained in the step 3, and then adding a trypsin solution into the solution to obtain a morchella in-vitro simulated intestine digest; 5, performing suction filtration and vacuum concentration on the product obtained in the step 4 to obtain the morchella in-vitro simulated digestive juice; and 6, uniformly mixing the morchella in-vitro simulated digestive juice with petroleum ether, and combining petroleum ether extracts to obtain morchella sterol. The morchella extract extracted by the method disclosed by the invention can relieve symptoms of ulcerative colitis induced by dextran sodium sulfate.
Owner:XIAN UNVERSITY OF ARTS & SCI
Application of lycium barbarum glycopeptide in preparation of medicine for preventing or treating inflammatory bowel disease
ActiveCN114209810AEarly chronic remissionEffective preventionAntipyreticDigestive systemAcute ulcerative colitisBowels diseases
The invention belongs to the field of medicines, and particularly relates to application of lycium barbarum glycopeptide in preparation of medicines for preventing or treating inflammatory bowel diseases. Experimental results of a dextran sodium sulfate (DSS)-induced mouse acute ulcerative colitis model show that the Chinese wolfberry glycopeptide can significantly advance the chronic remission period, significantly alleviate the acute colitis symptom, effectively reduce inflammatory response, and show an obvious anti-inflammatory effect. The experimental results show that the lycium barbarum glycopeptide as a traditional Chinese medicinal material extraction product can be effectively used for preventing and treating the inflammatory bowel disease, has the prospect of being developed into the medicine for preventing and treating the inflammatory bowel disease, provides more treatment choices for clinically preventing or treating the inflammatory bowel disease, and has important social benefits and economic values.
Owner:NINGXIA QIPEPTIDE TECH CO LTD
Chloroquine-coated denatured albumin nanoparticles for selectively resisting inflammatory cells as well as preparation method and application of chloroquine-coated denatured albumin nanoparticles
PendingCN114146065AImprove stabilityGood compatibilityOrganic active ingredientsAntipyreticNanoparti clesDextran
The invention discloses a chloroquine-coated denatured albumin nanoparticle for selectively resisting inflammatory cells as well as a preparation method and application thereof, and the denatured albumin nanoparticle is used as a carrier and is coated with a drug chloroquine. The nanoparticles have good stability and biocompatibility, can be efficiently internalized by macrophages, and can effectively aim at inflammatory cells at colon parts, so that inflammation is relieved, and the nanoparticles are used for treating colitis diseases caused by dextran sodium sulfate.
Owner:HEFEI UNIV OF TECH
Application of magnesium isoglycyrrhizinate to preparation of medicine for treating colitis
InactiveCN112043718AConvenient for clinical operationEasy to prepareOrganic active ingredientsAntipyreticInflammatory factorsDisease
The invention belongs to the technical field of pharmacy, and relates to an application of magnesium isoglycyrrhizinate to preparation of a medicine for treating colitis. In a disease model of mouse acute and chronic enteritis induced by dextran sodium sulfate DSS, the magnesium isoglycyrrhizinate can effectively improve the conditions of weight loss, diarrhea, hemafecia and colonic shortening ofmice, reduce inflammatory cell infiltration and the expression level of inflammatory factors in the colons of the mice, maintain the intestinal epithelial barrier integrity, increase connexins Zo-1, occludin and E-caderin, reduce the Claudin-2 expression level, and reduce fibrosis caused by colitis. It is found for the first time that the magnesium isoglycyrrhizinate can treat colitis, clinical application of the magnesium isoglycyrrhizinate is increased, and remarkable popularization value is achieved.
Owner:南京澳特飞吉生物科技有限公司
Application of momordica polysaccharide in preparation of medicine for treating ulcerative colitis and medicinal preparation thereof
ActiveCN112691114ARestore integrityReduced colitis in miceOrganic active ingredientsAntipyreticUlcerative colitisMomordica
The invention discloses application of momordica polysaccharide in preparation of a medicine for treating ulcerative colitis and a medicinal preparation thereof, and belongs to the field of biological medicine. The ulcerative colitis is induced by dextran sodium sulfate. Experiments show that the momordica polysaccharide reduces disease activity indexes and improves clinical symptoms by restoring body weight and excrement viscosity and reducing bleeding; an intestinal tract damaged by inflammation is protected by repairing the mucosal barrier function of a colon tissue; and immune system disorders of the ulcerative colitis are ameliorated by attenuating expression of inflammatory cytokines in the colon and reducing recruitment of CD4+T cells. The application field of the momordica polysaccharide is widened, an experimental basis is provided for clinical application of the momordica polysaccharide in preparation of the medicine for treating the ulcerative colitis, and the momordica polysaccharide has a good application prospect and huge potential value and social significance.
Owner:XUZHOU MEDICAL UNIV
Ulcerative colitis preventing baicalin-baicalein composition and preparation thereof
ActiveCN108743601AGood control effectPromote repairOrganic active ingredientsDigestive systemMedicineUlcerative colitis
The invention discloses an ulcerative colitis preventing baicalin-baicalein composition and a preparation thereof, and belongs to the technical field of traditional Chinese medicines. The compositioncomprises baicalin and baicalein at a mass ratio of 1-10 to 1. According to the invention, a dextran sulphate sodium salt induced ulcerative colitis mice model is adopted, the effect of baicalin-baicalein composition on model mouse is investigated on the aspects of states, pathomorphology and biochemical indicators; experimental results show that compared to baicalin or baicalein used alone, the composition has the good synergistic effect, has the better preventive and therapeutic effect on ulcerative colitis, and can significantly improve symptoms, relieve inflammatory reactions, and promotecolonic mucosal repairing.
Owner:JIANGSU UNIV
Application of eight-treasure pill to preparation of medicine for delaying occurrence and development of colitis-related colon cancer
PendingCN114869914AHeavy metal active ingredientsHydroxy compound active ingredientsStainingPharmaceutical drug
The invention relates to an application of Babaodan in preparation of a medicine for delaying occurrence and development of colitis-related colon cancer. Experimental results show that the eight-treasure pill can effectively slow down occurrence and development of azomethane oxide / dextran sodium sulfate induced colitis-related colon cancer. Meanwhile, HE staining results of the liver and the spleen show that compared with a blank control group, obvious histopathologic changes cannot be caused to the liver and the spleen after the mouse takes the eight-treasure pill for a long time, and the eight-treasure pill does not have obvious toxicity to the mouse after the mouse takes the eight-treasure pill for a long time.
Owner:XIAMEN TRADITIONAL CHINESE MEDICINE
Modified sodium humate and preparation method and application
ActiveCN111995767AObvious symptoms of enteritisImprove pathological manifestationsCompounds screening/testingOrganic chemistryEscherichia coliCarboxyl radical
The invention discloses modified sodium humate and a preparation method and application thereof. An enteritis model mouse with obvious small intestine inflammation is obtained; Kunming mice drink distilled water containing 3-4% of dextran sodium sulfate for 3-5 days, then 13-15 days later, Kunming mice drink 0.3-0.5% of modified sodium humate aqueous solution and 108 cfu / mL of escherichia coli K88bacterial liquid, alternating is conducted every other day, and an enteritis model is established and treated for 18 days in total; secondly, a sodium humate modification process is controlled; modified sodium humate with a specific molar ratio of phenolic hydroxyl to carboxyl is obtained; the preparation method mainly comprises the following steps of: weighing 100g of humic acid mineral powder with humic acid mass content of 45%, 6-12g of sodium hydroxide and 3-6g of sodium thiosulfate, adding 1000g of distilled water, stirring at 60-130 r / min, reacting at 80-120 DEG C for 60-120 minutes, and centrifuging at 4,200 r / min for 10 minutes; and putting a supernatant into a stainless steel tray, and drying in a drying oven at 80-180 DEG C until the weight is constant, thereby obtaining the modified sodium humate product.
Owner:山东亚太海华生物科技有限公司
Method for preparing zinc oxide nanorod-silver microdisk composite heterostructure
InactiveCN103240422BBroad absorption spectrumUnique electronic three-dimensional transmission characteristicsPolycrystalline material growthFrom normal temperature solutionsZinc nitrateZinc oxide nanorod
Owner:TONGJI UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com